Table of Contents
- Why Kratom Law Is So Fragmented Right Now
- The 7-OH Issue Changed the Debate
- States Are Splitting Between Regulation and Prohibition
- Utah Shows How These Fights Become Lawsuits
- Ohio Became a Major Scheduling Battleground
- More States Are Still Deciding Which Direction to Go
- What the 2025-2026 Legal Battles Really Mean
Why Kratom Law Is So Fragmented Right Now
For U.S. businesses, consumers, and advocates, the big kratom story in 2025 and 2026 is not a single national ban or a single national legalization push. It is fragmentation. States have moved in three different directions at once: some are adopting consumer-protection frameworks, some are targeting high-potency kratom-derived compounds such as 7-hydroxymitragynine, and some are still pursuing outright criminalization. At the federal level, there is still no uniform regulatory framework for kratom itself, and the FDA continues to state that there are no FDA-approved kratom drug products and that kratom is associated with significant safety concerns. See: FDA public health focus on kratom.
The 7-OH Issue Changed the Debate
That split has sharpened because 2025 brought a major distinction into focus: regulators increasingly treated traditional kratom leaf and high-potency 7-OH products as different policy problems. In July 2025, the FDA announced warning letters to seven firms marketing products containing 7-hydroxymitragynine, and later that month said it was specifically targeting 7-OH as a concentrated kratom byproduct with opioid-receptor activity, while noting that its action was not focused on natural kratom leaf products. That distinction has mattered politically, because it gave lawmakers a way to crack down on concentrated or synthetic-adjacent products without necessarily banning every kratom product outright. See: FDA warning letters on 7-hydroxymitragynine products.
Advocacy groups, especially the American Kratom Association, leaned hard into that separation during 2025. In January 2025, the AKA publicly warned consumers about mislabeled or deceptive 7-OH products and argued that products with elevated 7-OH levels should not be treated as traditional kratom. By July 2025, the group was openly supporting FDA enforcement against chemically manipulated 7-OH products, while continuing to defend access to natural kratom under consumer-protection rules rather than prohibition. That advocacy posture helps explain why many 2025-2026 legislative fights have centered less on kratom in the abstract and more on product standards, age gates, labeling, and alkaloid concentration limits. See: American Kratom Association consumer alert on 7-OH products.
For regulators, “what” is being sold—traditional leaf vs. chemically manipulated 7-OH products—has become just as important as “whether” kratom is allowed at all.
States Are Splitting Between Regulation and Prohibition
Colorado is one of the clearest examples of the regulatory model winning out over prohibition. Senate Bill 25-072 became law in 2025 and prohibits sales to anyone under 21, bars adulterated products, restricts products that exceed a set 7-hydroxymitragynine threshold, prohibits candy-like or child-appealing formats, and treats certain violations as deceptive trade practices under the Colorado Consumer Protection Act. In other words, Colorado did not criminalize kratom across the board; it moved toward a structured, consumer-protection framework aimed at product quality, youth access, and potency control.
South Carolina also moved into the regulated-access camp in 2025 by enacting the South Carolina Kratom Consumer Protection Act. The enacted law regulates retail and processor conduct instead of banning kratom outright, and the AKA celebrated the signing as a major advocacy win because the state had previously flirted with criminalization. But South Carolina also shows how unstable this policy area remains: by December 2025, a new bill had already been filed to add kratom to Schedule I and repeal the very consumer-protection framework the state had just adopted. That is one of the best illustrations of the current kratom battlefield: a state can move from regulation to renewed prohibition pressure in a matter of months.
Utah Shows How These Fights Become Lawsuits
Utah’s 2026 fight is especially important because it moved beyond advocacy and into direct litigation. Utah’s enrolled S.B. 45 requires kratom processors and retailers to register with the Department of Agriculture and Food, raises the sales age to 21, ties retail eligibility to tobacco-specialty licensing, and imposes product-registration and enforcement provisions. After passage, Botanic Tonics LLC sued, arguing that the law would effectively shut off sales of its kratom-and-kava product at hundreds of Utah retail locations. That makes Utah one of the most concrete 2026 examples of a kratom legal battle shifting from legislative debate to courtroom challenge over how restrictive a regulatory regime can become before companies attack it as economically destructive or legally defective.
Ohio Became a Major Scheduling Battleground
Ohio took a different path and became one of the most consequential scheduling battlegrounds in the country. The Ohio Board of Pharmacy’s December 12, 2025 notice made kratom-related products illegal to sell, possess, or distribute under an emergency rule, while clarifying that natural kratom in vegetation form was exempt from that specific rule. Then, in January 2026, the Board opened comment on proposed rules to classify both mitragynine-related compounds and mitragynine itself as Schedule I controlled substances. Ohio therefore became a live test case for how far state regulators may go in transforming kratom policy from product regulation into controlled-substance scheduling. See: Ohio Board of Pharmacy kratom-related products notice.
The Ohio fight also shows how fast the politics around kratom can turn on administrative action rather than a governor-signed bill. Analysis from Ohio State’s Drug Enforcement and Policy Center notes that Governor Mike DeWine pushed for scheduling in 2025, that the Board responded with emergency action against kratom-related products, and that the permanent rulemaking process then advanced in 2026. The American Kratom Association responded by accusing the Board of relying on weak science and poor process. Whether one agrees with that criticism or not, Ohio is a strong example of the next phase of kratom conflict: not just legislatures passing statutes, but agencies using rulemaking power to redraw the market. See: Ohio State Drug Enforcement and Policy Center analysis on regulating kratom.
More States Are Still Deciding Which Direction to Go
At the same time, several states in 2026 were still considering fresh legislation on both sides of the issue. California’s AB 1088 would create a kratom consumer-protection framework that includes child-resistant packaging, youth-sale restrictions, and controls on products attractive to children. Kansas’ SB 497 would go the other direction by adding kratom to Schedule I. Illinois’ SB 3160, labeled the Kratom Prohibition Act, would prohibit the purchase, possession, sale, or distribution of products containing kratom. Iowa likewise moved legislation to designate kratom as a Schedule I controlled substance. Those states matter because they show the national pattern is still unsettled: in 2026, lawmakers are not converging on one model. They are still actively choosing between regulated commerce and prohibition.
| State | Direction |
|---|---|
| California (AB 1088) | Consumer-protection framework |
| Kansas (SB 497) | Schedule I proposal |
| Illinois (SB 3160) | Kratom Prohibition Act |
| Iowa | Schedule I designation effort |
What the 2025-2026 Legal Battles Really Mean
The strongest practical takeaway from the 2025-2026 cycle is that kratom’s legal future in the United States will likely be shaped by the same question everywhere: is the target natural leaf kratom, or concentrated and chemically manipulated alkaloid products marketed under the kratom umbrella? That question now drives FDA enforcement, state consumer-protection laws, agency scheduling efforts, and business lawsuits. For the kratom industry and its opponents alike, the next wave of legal battles will likely be fought over that line. If states keep distinguishing traditional leaf products from high-potency 7-OH derivatives, regulation may continue to outperform outright prohibition in some jurisdictions. If they stop making that distinction, more states may follow Louisiana, which signed SB 154 in 2025 and made possession and distribution of kratom itself a criminal matter effective August 1, 2025.
Key Takeaway for 2025–2026
Across the U.S., kratom’s status is no longer a simple “legal vs. illegal” question. The decisive factor is increasingly whether a product is traditional leaf or a high-potency, chemically manipulated derivative.